Skip to main content
OpenTrials
Completed

NCT Number: NCT01903655

Study of the Telomere-telomerase System and the Expression of Candidate Genes in the Leukocytes of Patients With Depressive Disorder: Search for Peripheral Markers of Somatic Stress

The mechanisms of oxidative stress and inflammation involved in mood disorders are factors of chronicity and severity. These mechanisms induce a phenomenon of accelerated cellular senescence and are reflected by alterations in systemic gene expression detectable in leukocytes in peripheral blood. The genetic markers of these mechanisms are clinically significant markers. The identification of new genetic markers will make it possible to improve evaluations of the severity and somatic consequences of depressive syndromes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Depressive Disorder Mental Disorders Mood Disorders

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Dijon

Dijon, 21079, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Persons who have given their written informed consent
  • absence of a diagnosis of major depressive disorder throughout the study and no history of psychiatric disorders
  • diagnosis of a first episode of a major depressive disorder
  • diagnosis of a recurrent major depressive disorder (at least three episodes) with or without resistance to therapy

Remarks:

  • the diagnosis of major depressive disorder with characteristics of melancholy must be clearly mentioned in the case report form but is not a reason for not being included in the study
  • the presence of a recent or older attempted suicide must lead to a careful clinical assessment of the diagnosis of depressive disorder and must be clearly mentioned in the case report form.

Exclusion criteria

  • Persons not covered by the national Health Insurance Agency
  • Psychotic or bipolar disorders
  • Severe personality disorders
  • cardiovascular disease, proven inflammatory disease and cancer
  • persons unable to give their consent personally,
  • persons in emergency situations,
  • pregnant women,
  • breast-feeding women

Treatment and study plan

telomere length

Other

Primary outcomes

  1. Telomere length

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 6 months

Secondary outcomes

  1. level of oxidative stress.

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 6 months

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Jul 19, 2013
Registry last updated
Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.